Mark Spahr

Mark Spahr has extensive experience in the pharmaceutical industry. Mark began their career in 1990 as a Staff Immunologist at Merck, Sharpe and Dohme Pharmaceuticals, where they managed up to four concurrent projects and worked independently to create novel assays for cellular activation. In 1992, they joined Pfizer Global Research and Development as a Senior Scientist, where they managed up to five in-vitro colleagues on project teams responsible for experimental protocols, data analysis and quality control. Mark was also recognized as a technical and disease expert in Cardiovascular Pharmacology for lipid biochemistry, cellular biology, assay development and a significant scientific contributor to project teams. In 2008, they joined Cayman Chemical as a Technical Support Representative before joining Esperion Therapeutics, Plymouth, MI in 2010 as a Senior Scientist, Biology. In 2013, they moved to Lycera as a Senior Research Scientist, and in 2020, they joined IFM Therapeutics as a Sr. Research Associate.

Mark Spahr received their Masters in Microbiology and Immunology from the University of Michigan between 1986 and 1990.